Pelvic exenteration for primary and recurrent gynaecological malignancies

Johannes H.W. de Wilt(Radboud University Nijmegen), Anca C. Ansink(Erasmus MC Cancer Institute), A. Logmans(Erasmus MC Cancer Institute), Maarten Vermaas(Association of British Orchestras), Wim J. Kirkels(Erasmus MC), Diederik H.-J. van Leeuwen(Erasmus MC Cancer Institute), Cornelis Verhoef(Erasmus MC Cancer Institute)
European Journal of Obstetrics & Gynecology and Reproductive Biology
September 7, 2006
10.1016/j.ejogrb.2006.07.025
Cited by 38

Related Papers

The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
|Cancer Cell|2020|683
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
|European Urology|2015|639
Body composition and outcome in patients undergoing resection of colorectal liver metastases19
|British journal of surgery|2012|464
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome
|Journal of Clinical Oncology|2003|321
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
|PubMed|2001|309